Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 1.00 |
| ▸ | VCP | P55072 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.61 |
| ▸ | TLR4 | O00206 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527534 | 1.00 | FBP1 (1.00) | FBP1VCPMAOAMAOBNFE2L2 | |
| Diethylamine SCHEMBL7982944 | 0.88 | FBP1 (0.77) | FBP1VCPMAOAMAOBNFE2L2 | |
| SCHEMBL2285892 | 0.80 | FBP1 (0.67) | FBP1VCP | |
| SCHEMBL2285894 | 0.80 | FBP1 (0.67) | FBP1VCP | |
| SCHEMBL5211010 | 0.79 | FBP1 (0.85) | FBP1VCPMAOAMAOBTLR4 | |
| SCHEMBL1027330 | 0.78 | FBP1 (1.00) | FBP1VCPMAOAMAOBTLR4 | |
| SCHEMBL1937312 | 0.78 | FBP1 (1.00) | FBP1VCPMAOAMAOBTLR4 | |
| SCHEMBL12720865 | 0.78 | FBP1 (1.00) | FBP1VCPMAOAMAOBTLR4 | |
| SCHEMBL1027331 | 0.78 | FBP1 (1.00) | FBP1VCPMAOAMAOBTLR4 | |
| SCHEMBL8625803 | 0.78 | FBP1 (1.00) | FBP1VCPMAOBNFE2L2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-111116613-B | Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof | 湘潭大学 | 2021-04-23 | — | — | CN | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-4627896-A2 | 3D/2D PEROVSKITE SOLAR CELLS | ODTÜ-GÜNAM (TR) | 2025-10-08 | — | — | EP | disclosed |
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| CN-101048393-A | Substituted N-arylsulfonyl heterocyclic amines as gamma-secretase inhibitors | SCHERING CORP (US) | 2007-10-03 | — | — | CN | disclosed |
| CN-1882590-A | Fused heterocyclic compounds as serotonin receptor modulators | JOHNSON & JOHNSON (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | FBP1 1407/4885VCP 4294/4885MAOA 868/4885 |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | FBP1 3079/4885VCP 4353/4885MAOA 507/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885VCP 4173/4885MAOA 28/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | FBP1 794/4885VCP 3713/4885MAOA 1257/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | FBP1 1093/4885VCP 4173/4885MAOA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.